Skip to main content

Table 1 Analytical specificity and sensitivity of the DBS eluate testing for markers of HBV, HCV and HIV infections compared to serum analyses

From: Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots - performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification

Parameters

Serum

DBS eluates

Specificity (%)/ 95% CIa)

Sensitivity (%)/ 95% CIa)

 

n. d. (N)

pos. (N)

n. d. (N)

pos. (N)

  

HBV

      

 HBsAg

159

140

161

138

100/97.7 – 100

98.6/94.9 – 99.8

 Anti-HBc

101

204

129b)

176b)

100/97.2 – 100

86.3/83.0 – 91.8b)

107c)

198c)

97.1/93.9 – 99.0c)

 Anti-HBs

153

157

162b)

148b)

100/97.6 – 100

94.3/90.0 – 97.5b)

157c)

153c)

97.5/93.8 – 99.3c)

 HBV DNA

50

100

107

93

100/96.1 – 100

93.0/92.9 – 93.1

HCV

      

 Anti-HCV

160

179

164

175

100/97.7 – 100

97.8/96.0 – 100

 HCV RNA

50

100

50

100

100/96.1 – 100

100/98.0 – 100

HIV

      

 HIV-1-p24/anti-HIV 1/2

97

112

97

112

100/96.3 – 100

100/96.8 – 100

  1. The results of the serum analyses served as reference for the calculation of the analytical performance characteristics of the DBS testing. — n. d.: not detectable; pos.: positive.
  2. a) 95% confidence interval calculated according to Clopper and Paerson [50]. b) Calculated with inclusion of the results obtained from HIV infected individuals. c) Calculated without the results recorded from HIV infected individuals.